# A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

> **NCT00797745** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 111 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** peginterferon alfa 2b
- **DRUG:** ribavirin
- **DRUG:** SCH 900518
- **DRUG:** ritonavir

## Key facts

- **NCT ID:** NCT00797745
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-07
- **Final completion:** 2010-09
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00797745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00797745, "A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00797745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*